News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zhejiang Hisun Pharma Enters Biosimilar Business With Catalent Pharma Solutions' Help



4/14/2014 2:37:24 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

April 14, 2014 -- Zhejiang Hisun Pharma signed an agreement with Catalent Pharma Solutions of the US under which Catalent will provide Hisun with biosimilar cell lines. Hisun will use the technology to produce biosimilars of well-known biologics, including two arthritis treatments, Remicade (infliximab) and Humira (adalimumab), plus a treatment for leukemia, Campath (alemtuzumab). According to Catalent, its GPEx® technology reduces development time by two-thirds. More details....

Stock Symbol: (SHA: 600267)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES